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The diversity of regulatory genetic variants and their
mechanisms of action reflect the complexity and
context-specificity of gene regulation. Regulatory
variants are important in human disease and defining
such variants and establishing mechanism is crucial to
the interpretation of disease-association studies. This
review describes approaches for identifying and
functionally characterizing regulatory variants,
illustrated using examples from common diseases.
Insights from recent advances in resolving the
functional epigenomic regulatory landscape in which
variants act are highlighted, showing how this has
enabled functional annotation of variants and the
generation of hypotheses about mechanism of action.
The utility of quantitative trait mapping at the
transcript, protein and metabolite level to define
association of specific genes with particular variants
and further inform disease associations are reviewed.
Establishing mechanism of action is an essential step
in resolving functional regulatory variants, and this
review describes how this is being facilitated by new
methods for analyzing allele-specific expression,
mapping chromatin interactions and advances in
genome editing. Finally, integrative approaches are
discussed together with examples highlighting how
defining the mechanism of action of regulatory
variants and identifying specific modulated genes
can maximize the translational utility of genome-wide
association studies to understand the pathogenesis
of diseases and discover new drug targets or
opportunities to repurpose existing drugs to treat them.Correspondence: julian@well.ox.ac.uk
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Regulatory genetic variation is important in human dis-
ease. The application of genome-wide association studies
(GWAS) to common multifactorial human traits has re-
vealed that most associations arise in non-coding DNA
and implicate regulatory variants that modulate gene ex-
pression [1]. Gene expression occurs in a dynamic func-
tional epigenomic landscape in which the majority of
genomic sequence is proposed to have regulatory poten-
tial [2]. Inter-individual variation in gene expression has
been found to be heritable and can be mapped as quan-
titative trait loci (QTLs) [3,4]. Such mapping studies re-
veal that genetic associations with gene expression are
common, that they often have large effect sizes, and that
regulatory variants act locally and at a distance to modu-
late a range of regulatory epigenetic processes, often in a
highly context-specific manner [5]. Indeed, the mode of
action of such regulatory variants is very diverse, reflect-
ing the complexity of mechanisms regulating gene ex-
pression and their modulation by environmental factors
at the cell, tissue or whole-organism level.
Identifying regulatory variants and establishing their
function is of significant current research interest as we
seek to use GWAS for drug discovery and clinical bene-
fit [6,7]. GWAS have identified pathways and molecules
that were not previously thought to be involved in dis-
ease processes and that are potential therapeutic targets
[8,9]. However, for the majority of associations, the iden-
tity of the genes involved and their mechanism of action
remain unknown, which limits the utility of GWAS. An
integrated approach is needed, taking advantage of new
genomic tools to understand the chromatin landscape,
interactions and allele-specific events, and reveal de-
tailed molecular mechanisms.
Here I review approaches to understanding regulatory
variation, from the viewpoint of both researchers needing
to identify and establish the function of variants underlying
a particular disease association, and those seeking to define
the extent of regulatory variants and their mechanism of
action at a genome-wide scale. I describe the importancehe licensee has exclusive rights to distribute this article, in any medium, for 12
e, the article is available under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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variants, including defining the disease-relevant epige-
nomic landscape in which variants operate, to enable func-
tional annotation. I highlight the utility of eQTL studies for
linking variants with altered expression of genes and the
experimental approaches for establishing function, includ-
ing descriptions of recent techniques that can help. I pro-
vide a strategic view, illustrated by examples from human
disease, that is relevant to variants occurring at any gen-
omic location, whether in classical enhancer elements or
other locations where there is the potential to modulate
gene regulation.
Regulatory variants and gene expression
Regulatory variation most commonly involves single-
nucleotide variants (SNVs) but also encompasses a range
of larger structural genomic variants that can affect gene
expression, including copy number variation [10]. Gene
regulation is a dynamic, combinatorial process involving a
variety of elements and mechanisms that may only operate
in particular cell types, at a given stage in development
or in response to environmental factors [11,12]. Various
events that are critical to gene expression are modu-
lated by genetic variation: transcription factor binding
affinity at enhancer or promoter elements; disruption of
chromatin interactions; the action of microRNAs or
chromatin regulators; alternative splicing; and post-
translational modifications [13,14]. Classical epigenetic
marks such as DNA methylation, chromatin state or ac-
cessibility can be modulated directly or indirectly by
variants [15-18]. Changes in transcription factor bind-
ing related to sequence variants are thought to be a
principal driver of changes in histone modifications, en-
hancer choice and gene expression [17-19].
Functional variants can occur at both genic and inter-
genic sites, with consequences that include both up- and
down-regulation of expression, differences in the kinetics
of response or altered specificity. The effect of regulatory
variants depends on the sequences that they modulate
(for example, promoter or enhancer elements, or encoded
regulatory RNAs) and the functional regulatory epige-
nomic landscape in which they occur. This makes regula-
tory variants particularly challenging to resolve, as this
landscape is typically dynamic and context specific. De-
fining which sequences are modulated by variants has
been facilitated by several approaches: analysis of signa-
tures of evolutionary selection and sequence conserva-
tion; experimental identification of regulatory elements;
and epigenomic profiling in model organisms, and more
recently in humans, for diverse cell and tissue types and
conditions [15,20].
The understanding of the consequences of genetic vari-
ation for gene expression provides a more tractable inter-
mediate molecular phenotype than a whole-organismphenotype, where confounding by other factors increases
heterogeneity. This more direct relationship with under-
lying genetic diversity might account in part for the suc-
cess of approaches resolving association with transcription
of sequence variants, such as eQTL mapping [3,5].
Regulatory variants, function and human disease
The heritable contribution to common polygenic dis-
ease remains challenging to resolve, but GWAS have
now mapped many loci with high statistical confidence.
Over 90% of trait-associated variants are found to be lo-
cated in non-coding DNA, and they are significantly
enriched in chromatin regulatory features, notably DNase
I hypersensitive sites [21]. Moreover, there is significant
overrepresentation of GWAS variants in eQTL studies,
implicating regulatory variants in a broad spectrum of
common diseases [7].
Several studies have identified functional variants involv-
ing enhancer elements and altered transcription factor
binding. These include a GWAS variant associated with
renal cell carcinoma that results in impaired binding and
function of hypoxia inducible factor at a novel enhancer of
CCND1 [22]; a common variant associated with fetal
hemoglobin levels in an erythroid-specific enhancer [23];
and germline variants associated with prostate and colo-
rectal cancer that modulate transcription factor binding at
enhancer elements involving looping and long-range inter-
actions with SOX9 [24] and MYC [25], respectively.
Multiple variants in strong linkage disequilibrium (LD)
identified by GWAS can exert functional effects through
various different enhancers, resulting in cooperative effects
on gene expression [26].
Functional variants in promoters have also been identi-
fied that are associated with disease. These include the ex-
treme situation in which a gain-of-function regulatory
SNV created a new promoter-like element that recruits
GATA1 and interferes with expression of downstream α-
globin-like genes, resulting in α-thalassemia [27]. Other
examples include a Crohn’s-disease-associated variant in
the 3’ untranslated region of IRGM that alters binding by
the microRNA mir-196, enhancing mRNA transcript sta-
bility and altering the efficacy of autophagy, thus affecting
the anti-bacterial activity of intestinal epithelial cells [28].
Some SNVs show significant association with differences
in alternative splicing [29], which may be important for
disease, as illustrated by a variant of TNFRSF1A associated
with multiple sclerosis, which encodes a novel form of
TNFR1 that can block tumor necrosis factor [30]. Disease-
associated SNVs can also modulate DNA methylation
resulting in gene silencing, as illustrated by a variant in a
CpG island associated with increased methylation of the
HNF1B promoter [31].
To identify functional variants, fine mapping of GWAS
signals is vital. This can be achieved by using large sample
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tion, and involving diverse populations to maximize statis-
tical confidence and resolve LD structure. Interrogation of
available functional genomic datasets to enable functional
annotation of identified variants and association with
genes based on eQTL mapping is an important early step
in prioritization and hypothesis generation. However, such
analysis must take note of what is known of the patho-
physiology of the disease, because the most appropriate
cell or tissue type needs to be considered given the
context-specificity of gene regulation and functional vari-
ants. Two case studies (Box 1) illustrate many of the dif-
ferent approaches that can be used to investigate the role
of regulatory variants in loci identified by GWAS. These
provide context for a more detailed discussion of tech-
niques and approaches in the remainder of this review.
Mapping regulatory variation
This section describes approaches and tools for func-
tional annotation of variants, considering in particular
the usefulness of resolving the context-specific regula-
tory epigenomic landscape and of mapping gene expres-
sion as a quantitative trait of transcription, protein or
metabolites.
Functional annotation and the regulatory epigenomic
landscape
High-resolution epigenomic profiling at genome-wide
scale using high-throughput sequencing (HTS) has en-
abled annotation of the regulatory landscape in which
genetic variants are found and may act. This includes
mapping regulatory features based on:
 chromatin accessibility using DNase I hypersensitivity
(DNase-seq) mapping [32,33] and post-translational
histone modifications by chromatin immunoprecipitation
combined with HTS (ChIP-seq) [34] that indicate the
location of regulatory elements such as enhancers;
 chromatin conformation capture (3C), which can be
scaled using HTS to enable mapping of genome-wide
interactions for all loci (Hi-C) [35] or for selected
target regions (Capture-C) [36];
 targeted arrays or genome-wide HTS to define
differential DNA methylation [15]; the non-coding
transcriptome using RNA-seq to resolve short and
long non-coding RNAs with diverse roles in gene
regulation [37] that may be modulated by underlying
genetic variation with consequences for common
disease [38].
The ENCyclopedia Of DNA Elements (ENCODE) Pro-
ject [2] has generated epigenomic maps for diverse human
cell and tissue types, including chromatin state, transcrip-
tional regulator binding and RNA transcripts, that havehelped to identify and interpret functional DNA elements
[20] and regulatory variants [1,39]. Enhancers, promoters,
silencers, insulators and other regulatory elements can be
context specific; this means that generating datasets for
particular cellular states and conditions of activation of
pathophysiological relevance will be necessary if we are to
use such data to inform our understanding of disease.
There is also a need to increase the amount of data gener-
ated from primary cells given the caveats inherent to im-
mortalized or cancer cell lines. For example, although
studies in lymphoblastoid cell lines (LCLs) have been
highly informative [40], their immortalization using the
Epstein-Barr virus may alter epigenetic regulation or
specific human genes, notably DNA methylation, and ob-
served levels of gene expression, affecting the interpret-
ation of the effects of variants [41,42]. As part of ongoing
efforts to expand the diversity of primary cell types and
tissues for which epigenomic maps are available, the Inter-
national Human Epigenome Consortium, which includes
the NIH Roadmap Epigenetics Project [43] and BLUE-
PRINT [44], seeks to establish 1,000 reference epigenomes
for diverse human cell types.
The FANTOM5 project (for ‘functional annotation of
the mammalian genome 5’) has recently published work
complementing and extending ENCODE by using cap ana-
lysis of gene expression (CAGE) and single-molecule se-
quencing to define comprehensive atlases of transcripts,
transcription factors, promoters, enhancers and transcrip-
tional regulatory networks [45,46]. This includes high-
resolution context-specific maps of transcriptional start
sites and their usage for 432 different primary cell types,
135 tissues and 241 cell lines, enabling promoter-level
characterization of gene expression [46]. The enhancer
atlas generated by FANTOM5 defines a map of active en-
hancers that are transcribed in vivo in diverse cell types
and tissues [45]. It builds on the recognition that enhancers
can initiate RNA polymerase II transcription to produce
eRNAs (short, unspliced, nuclear non-polyadenylated non-
coding RNAs) and act to regulate context-specific expres-
sion of protein-coding genes [45]. Enhancers defined by
FANTOM5 were enriched for GWAS variants; the context
specificity is exemplified by the fact that GWAS variants
for Graves’ disease were enriched predominantly in en-
hancers expressed in thyroid tissue [45].
Publicly accessible data available through genome
browsers significantly enhances the utility to investiga-
tors of ENCODE, FANTOM5 and other datasets that
allow functional annotation and interpretation of regula-
tory variants, while tools integrating datasets in a search-
able format further enable hypothesis generation and
identification of putative regulatory variants (Table 1)
[39,47,48]. The UCSC Genome Browser, for example, in-
cludes a Variant Annotation Integrator [49], and the
Ensembl genome browser includes the Ensembl Variant
Box 1. Case studies in defining regulatory variants
SORT1, LDL cholesterol and myocardial infarction
A pioneering study by Musunuru and colleagues published in 2010 [100] demonstrated how the results of a GWAS for a human disease
and linked biochemical trait could be taken forward to establish mechanism and function involving regulatory variants using a
combination of approaches. Myocardial infarction and plasma levels of low-density lipoprotein cholesterol (LDL-C) are strongly
associated with variants at chromosome 1p13 [101]. The authors [100] fine mapped the association and defined haplotypes and LD
structure through analysis of populations of African ancestry. A combination of systematic reporter gene analysis in a
pathophysiologically relevant human hepatoma cell line using human bacterial artificial chromosomes spanning the 6.1 kb region
containing the peak LD SNPs together with eQTL
analysis established that a SNV, rs12740374, was associated with allele-specific differences in expression. eQTL analysis showed
association with three genes, most notably with SORT1 (higher expression was associated with minor allele at the transcript
and protein level), and the effects were seen in liver but not subcutaneous and omental intestinal fat. The minor allele created a
predicted binding site for C/EBP transcription factors, and allele-specific differences were seen using electrophoretic mobility shift assays
and ChIP. Manipulating levels of C/EBP resulted in loss or gain of allelic effects on reporter gene expression and, in cells of different
genotypic background, effects could be seen on SORT1 expression; human embryonic stem cells were used to show that this was
specific to hepatocyte differentiation. Small interfering (siRNA) knockdown and viral overexpression studies of hepatic Sort1 in
humanized mice with different genetic backgrounds demonstrated a function for Sort1 in altering LDL-C and very-low-density
lipoprotein (VLDL) levels by modulating hepatic VLDL
secretion. A genomic approach thus identified SORT1 as a
novel lipid-regulating gene and the sortilin pathway as a target for potential therapeutic intervention [100].
FTO, RFX5 and obesity: effects at a distance
Regulatory variants may modulate expression of the most proximal gene, but they can have effects at a significant distance (for
example, by DNA looping or modulation of a gene network) making resolution of the functional basis of GWAS signals of association
difficult [55]. Recent work on obesity-associated variants in the dioxygenase FTO [102] highlights this and illustrates further approaches
that can be used to investigate GWAS signals and the functional significance of regulatory variants. A region spanning introns 1 and 2 of
the FTO gene shows highly significant association with obesity by GWAS [103-105]. Following this discovery, FTO was found to encode
an enzyme involved in control of body weight and metabolism based on evidence from FTO-deficient mice [106] and from a study of
mouse overexpression phenotypes in which additional copies of the gene led to increased food intake and obesity [107]. There was not,
however, evidence linking the GWAS variants or associated region with altered FTO expression or function. Smemo and colleagues [102]
considered the wider regulatory landscape of FTO and mapped the regulatory interactions between genomic loci using 3C. Strikingly,
their initial studies in mouse embryos revealed that the intronic GWAS locus showed physical interactions not only with the Fto
promoter but also with the Irx3 gene (encoding a homeodomain transcription factor gene expressed in the brain) over 500 kb away.
The interaction with Irx3 was confirmed in adult mouse brains and also human cell lines and zebrafish embryos. Data from the ENCODE
project showed that the intronic FTO GWAS region is conserved, and its chromatin landscape suggested multiple regulatory features
based on chromatin marks, accessibility and transcription factor binding. Smemo et al. [102] then established that the sequences have
enhancer activity in relevant mouse tissues, showing that expression of Irx3 depends on long-range elements. Strikingly, the GWAS variants
associated with obesity showed association with levels of expression of IRX3 but not of FTO in human brain samples. Moreover, Irx3 knockout
mice showed up to 30% reduction in body weight through loss of fat mass and increased basal metabolic rate, revealing a previously
unrecognized role for IRX3 in regulating body weight. The multifaceted approach adopted by Smemo and colleagues [102] illustrates several
of the approaches that can be used to define regulatory variants and the benefits of using data generated from humans and model
organisms. However, the question of what the causal functional variants are and the molecular/physiological mechanisms involving IRX3 and
FTO remain the subject for further work.
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base enables annotations for particular variants to be
accessed. RegulomeDB combines data from ENCODE
and other datasets, including manually curated genomicregions for which there is experimental evidence of func-
tionality; chromatin state data; ChIP-seq data for regula-
tory factors; eQTL data; and computational prediction of
transcription factor binding and motif disruption by
Table 1 Examples of online data resources and tools for analysis of putative regulatory variants
Name Description URL
ENCODE Encyclopedia of DNA Elements Project https://www.encodeproject.org





International Human Epigenome Consortium
Data Portal
http://ihec-epigenomes.org/outcomes/ihec-data-portal/
Roadmap Epigenomics Project NIH Roadmap Epigenomics Mapping Consortium,
including links to data
http://www.roadmapepigenomics.org
BLUEPRINT European hematopoietic epigenome project http://www.blueprint-epigenome.eu
Variant Annotation Integrator (UCSC) Tool for predicting functional effects of variants
on transcripts
http://www.noncode.org/cgi-bin/hgVai
Variant Effect Predictor (Ensembl) Integrated tool resolving effects of variant on
regulatory regions, genes, transcripts and protein
http://www.ensembl.org/info/docs/tools/vep/index.html
RegulomeDB Tool for functional annotation of SNVs including
known and predicted regulatory elements and eQTLs
http://regulomedb.org
SNPnexus Integrated functional annotation of SNVs http://snp-nexus.org/about.html
JASPAR Transcription factor binding profile database http://jaspar.genereg.net
PROMO Transcription factor binding site analysis http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/
promoinit.cgi?dirDB=TF_8.3
MAPPER2 Identification of transcription factor binding sites
in multiple genomes
http://genome.ufl.edu/mapper/
HaploReg Functional annotation of variants on haplotype
blocks such as at GWAS loci
http://www.broadinstitute.org/mammals/haploreg/
haploreg.php
GWAS3D Integrated annotation of variants including
chromatin interactions
http://jjwanglab.org/gwas3d
ORegAnno Regulatory annotation database http://www.oreganno.org/oregano/
ConSite Transcription factor binding site detection using
phylogenetic footprinting
http://consite.genereg.net
HGMD Human Gene Mutation Database, including
regulatory mutations
http://www.hgmd.org
Genevar eQTL database integration, search and visualization http://www.sanger.ac.uk/resources/software/genevar/
eQTL Browser NCBI hosted browser to interrogate eQTL datasets http://www.ncbi.nlm.nih.gov/projects/gap/eqtl/index.cgi
OMICStools Links to a large number of multi-omics tools http://omictools.com
eQTL, expression quantitative trait locus; GWAS, genome-wide association study; SNV, single-nucleotide variant.
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lished a Combined Annotation-Dependent Depletion
method involving 63 types of genomic annotation to es-
tablish genome-wide likelihoods of deleteriousness for
SNVs and small insertion-deletions (indels), which helps
to prioritize functional variants.
Determining which variants are located in regulatory
regions is further helped by analysis of conservation of
DNA sequences across species (phylogenetic conserva-
tion) to define functional elements. Lunter and col-
leagues [51] recently reported that 8.2% of the human
genome is subject to negative selection and is likely to
be functional. Claussnitzer and colleagues [52] studied
conservation of transcription factor binding sites in cis-
regulatory modules. They found that the regulation in-
volving such sequences was combinatorial and depended
on complex patterns of co-occurring binding sites [52].Application of their ‘phylogenic module complexity ana-
lysis’ approach to type 2 diabetes GWAS loci revealed a
functional variant in the PPARG gene locus that altered
binding of the homeodomain transcription factor PRRX1.
This was experimentally validated using allele-specific ap-
proaches and effects on lipid metabolism and glucose
homeostasis were demonstrated.
Insights from transcriptome, proteome, and metabolome
QTLs
Mapping gene expression as a quantitative trait is a power-
ful way to define the regions and markers associated with
differential expression between individuals [53]. Applica-
tion in human populations has enabled insights into the
genomic landscape of regulatory variants, generating maps
that are useful for GWAS, sequencing studies and other
settings where the function of genetic variants is sought
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at a distance are likely to be trans-acting. Resolution of
trans-eQTLs is challenging, requiring large sample sizes
owing to the number of comparisons performed, because
all genotyped variants in the genome can be considered for
association. However, this resolution is important given
how informative eQTLs can be for defining networks,
pathways and disease mechanism [55]. When combined
with cis-eQTL mapping, trans-eQTL analysis allows dis-
covery of previously unappreciated relationships between
genes, as a variant showing local cis association with
expression of a gene might also be found to show trans
association with one or more other genes (Figure 1). For
example, in the case of a cis-eQTL involving a transcrip-
tion factor gene, these trans-associated genes might be
regulated by that transcription factor (Figure 1c). This can
be very informative when investigating loci found in
GWAS; for example, a cis-eQTL for the transcription fac-
tor KLF14 that is also associated with type 2 diabetes and
high-density lipoprotein cholesterol was found to act as a
master trans regulator of adipose gene expression [56].
Trans-eQTL analysis is also a complementary method to
ChIP-seq for defining transcription factor target genes [57].
For other cis-eQTLs, the trans-associated genes might be
part of a signaling cascade (Figure 1d), which might be well
annotated (for example a cis-eQTL involving IFNB1 is as-
sociated in trans with a downstream cytokine network) or
provide new biological insights [57].
eQTLs are typically context specific, dependent for
example on cell type [58-60] and state of cellular activa-
tion [57,61,62]. Careful consideration of relevant cell
types and conditions is therefore needed when investi-
gating regulatory variants for particular disease states.
For example, eQTL analysis of the innate immune
response transcriptome in monocytes defined associa-
tions involving canonical signaling pathways, key com-
ponents of the inflammasome, downstream cytokines
and receptors [57]. In many cases these were disease-
associated variants and were identified only in induced
monocytes, generating hypotheses for the mechanism
of action of reported GWAS variants. Such variants
would not have been resolved if only resting cells had
been analyzed [57]. Other factors can also be significant
modulators of observed eQTLs, including age, gender,
population, geography and infection status, and they
can provide important insights into gene-environment
interactions [62-66].
The majority of published eQTL studies have quantified
gene expression using microarrays. Application of RNA-
seq enables high-resolution eQTL mapping, including as-
sociation with abundance of alternatively spliced tran-
scripts and quantification of allele-specific expression
[40,67]. The latter provides a complementary mapping ap-
proach to define regulatory variants.In theory, eQTLs defined at the transcript level might
not be reflected at the protein level. However, recent
work by Kruglyak and colleagues [68] in large, highly
variable yeast populations using green fluorescent pro-
tein tags to quantify single-cell protein abundance has
shown good correspondence between QTLs influencing
mRNA and protein abundance; genomic hotspots were
associated with variation in abundance of multiple pro-
teins and modulating networks.
Mapping protein abundance as a quantitative trait (pQTL
mapping) is important in ongoing efforts to understand
regulatory variants and the functional follow-up of GWAS.
However, a major limitation has been availability of appro-
priate high-throughput methods for quantification. A
highly multiplexed proteomic platform involving modified
aptamers was used to map cis-regulated protein expres-
sion in plasma [69], and micro-western and reverse-phase
protein arrays enabled 414 proteins to be assayed simul-
taneously in LCLs, resolving a pQTL involved in the re-
sponse to chemotherapeutic agents [70]. The application
of state-of-the-art mass spectrometry-based proteomic
methods is enabling quantification of protein abundance
for pQTL mapping. There are still limitations, however, in
the extent, sensitivity and dynamic range that can be
assayed, the availability of analysis tools, and challenges in-
herent in studying the highly complex and diverse human
proteome [71].
There are multiple ways in which genetic variation can
modulate the nature, abundance and function of proteins,
including effects of non-coding variants on transcription,
regulation of translation and RNA editing, and alternative
splicing. In coding sequences, non-synonymous variants
can also affect regulation of splicing and transcript stabil-
ity. An estimated 15% of codons have been proposed by
Stergachis and colleagues [72] to specify both amino acids
and transcription factor binding sites; they found evidence
that the latter resulted in codon constraint through evolu-
tionary selective pressure, and that coding SNVs directly
affected the resultant transcription factor binding. It re-
mains unclear to what extent sequence variants modulate
functionally critical post-translational modifications, such
as phosphorylation, glycosylation and sulfation.
The role of genetic variation in modulating human
blood metabolites was highlighted by a recent large
study by Shin and colleagues [73] of 7,824 individuals, in
which 529 metabolites in plasma or serum were quanti-
fied using liquid-phase chromatography, gas chromatog-
raphy and tandem mass spectrometry. This identified
genome-wide associations at 145 loci. For specific genes,
there was evidence of a spectrum of genetic variants
ranging from very rare loss-of-function alleles leading to
metabolic disorders to common variants associated with
molecular intermediate traits and disease. Availability of
eQTL data through gene expression profiling at the
Figure 1 Examples of local and distant effects of regulatory variants. (a) A local cis-acting variant (red star, top) in a regulatory element
(red line) affects allele-specific transcription factor binding affinity and is associated with differential expression of gene A (as shown by the chart,
bottom), with possession of a copy of the A allele associated with higher expression than the G allele (hence AA homozygotes having higher
expression than AG heterozygotes, with lowest expression in GG homozygotes). (b) The same variant can modulate expression of gene D at
a distance through DNA looping that brings the regulatory enhancer element close to the promoter of gene D (gray line) on the same
chromosome. (c) An example of a local cis-acting variant modulating expression of a transcription factor encoding gene, Gene E, differential
expression of which modulates a set of target genes. Expression of these target genes is found to be associated in trans with the variant
upstream of gene E. (d) A local cis-acting variant on chromosome 12 modulates expression of a cytokine gene and is also associated in trans
with a set of genes whose expression is regulated through a signaling cascade determined by that cytokine. Such trans associations can be
shown on a circos plot (chromosomes labeled 1-22 with arrows pointing to location of gene on a given chromosome).
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Mendelian randomization analysis (a method for asses-
sing causal associations in observational data that are
based on the random assortment of genes from parents
to offspring [74]) to search for a causal relationship be-
tween differential expression of a gene and metabolite
levels using genetic variation as an instrumental variable.
There were limitations due to study power but a causal
role for some eQTLs in metabolic trait associations was
defined, including for the acyl-CoA thioesterase THEM4
and the cytochrome P450 CYP3A5 genes [73].
Finally, analysis of epigenetic phenotypes as quantitative
traits has proved very informative. Degner and colleagues
[16] analyzed DNase-I hypersensitivity as a quantitative
trait (dsQTLs) in LCLs. Many of the observed dsQTLs
were found to overlap with known functional regions,
show allele-specific transcription factor binding and also
show evidence of being eQTLs. Methylation QTL
(meQTL) studies have also been published for a variety of
cell and tissue types that provide further insight in regula-
tory functions of genomic variants [75-77]. A meQTL
study in LCLs revealed significant overlap with other epi-
genetic marks, including histone modifications and
DNase-I hypersensitivity, and also with up- and down-
regulation of gene expression [77]. Altered transcription
factor binding by variants was found to be a key early step
in the regulatory cascade that may result in altered methy-
lation and other epigenetic phenomena [77].
Methods for functional validation of variants
In this section I review different approaches and meth-
odologies that can help establish mechanism for regula-
tory variants. These tools can be used to test hypotheses
that have been generated from functional annotation of
variants and eQTL mapping. In some instances, data will
be publicly available through repositories or accessible
through genome browsers to enable analysis (Table 1),
for example in terms of allele-specific expression or
chromatin interactions, but as previously noted the ap-
plicability and relevance of this information needs to be
considered in the context of the particular variant and
disease phenotype being considered. New data may need
to be generated by the investigator. For both allele-
specific gene expression and chromatin interactions, the
new data can be analyzed in a locus-specific manner
without the need for high-throughput genomic tech-
nologies, but equally it can be cost- and time-effective to
screen many different loci simultaneously. A variety of
other tools can be used to characterize variants, includ-
ing analysis of protein-DNA interactions and reporter
gene expression (Box 1). New genome editing tech-
niques provide an exciting, tractable approach for study-
ing human genetic variants, regulatory elements and
genes in a native chromosomal context.Allele-specific transcription
Cis-acting regulatory variants modulate gene expression
on the same chromosome. Resolution of allele-specific
differences in transcription can be achieved using tran-
scribed SNVs to establish the allelic origin of transcripts
in individuals heterozygous for those variants [78]. Alter-
natively, it is possible to use proxies of transcriptional
activity, such as phosphorylated RNA polymerase II (Pol
II), to expand the number of informative SNVs, as these
are not restricted to transcribed variants and can include
any SNVs within about 1 kb of the gene when analyzed
using allele-specific Pol II ChIP [79]. Early genome-wide
studies of allele-specific expression showed that, in addition
to the small number of classical imprinted genes showing
monoallelic expression, up to 15 to 20% of autosomal genes
show heritable allele-specific differences (typically 1.5- to
2-fold in magnitude), consistent with the widespread and
significant modulation of gene expression by regulatory
variants [80]. Mapping allele-specific differences in tran-
script abundance is an important complementary approach
to eQTL mapping, as shown by recent high-resolution
RNA-seq studies [40,81]. Lappalainen and colleagues [40]
analyzed LCLs from 462 individuals from diverse popula-
tions in the 1000 Genomes Project. An integrated analysis
showed that almost all the identified allele-specific differ-
ences in expression were driven by cis-regulatory variants
rather than genotype-independent allele-specific epigenetic
effects. Rare regulatory variants were found to account for
the majority of identified allele-specific expression events
[40]. Battle and colleagues [81] mapped allele-specific gene
expression as a quantitative trait using RNA-seq in whole
blood from 922 individuals, showing that this method is
complementary to cis-eQTL mapping and can provide
mechanistic evidence of regulatory variants acting in cis.
Allele-specific transcription factor recruitment provides
further mechanistic evidence for how regulatory variants
act. Genome-wide analyses - for example, of binding of
the NF-κB transcription factor family by ChIP-seq [82] -
have provided an overview of the extent of such events,
but such datasets currently remain limited in terms of the
numbers of individuals and transcription factors profiled.
For some putative regulatory variants, predicting conse-
quences for transcription factor binding by modeling
using position-weighted matrices has proved powerful
[83], and this can be improved using flexible transcription
factor models based on hidden Markov models to repre-
sent transcription factor binding properties [84]. Experi-
mental evidence for allele-specific differences in binding
affinity can be generated using highly sensitive in vitro ap-
proaches such as electrophoretic mobility shift assays,
while ex vivo approaches such as ChIP applied to hetero-
zygous cell lines or individuals can provide direct evidence
of relative occupancy by allele [85]. A further elegant ap-
proach is the use of allele-specific enhancer trap assays,
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regulatory SNP in a functional p53 binding site [86].
Chromatin interactions and DNA looping
Physical interactions between cis-regulatory elements
and gene promoters can be identified by chromatin con-
formation capture methods, which provide mechanistic
evidence to support hypotheses regarding the role of dis-
tal regulatory elements in modulating expression of par-
ticular genes and how this may be modulated by specific
regulatory genetic variants. For some loci and target re-
gions, 3C remains an informative approach, but typically
investigators following up GWAS have several associated
loci of interest to interrogate. Here, use of the Capture-
C approach [36] (Figure 2) developed by Hughes and
colleagues holds considerable promise: this high-
throughput approach enables mapping of genome-wide
interactions for several hundred target genomic regions
spanning expression-associated variants and putative
regulatory elements at high resolution. To complement
and confirm those results it is also possible to analyze
promoters of expression-associated genes as target re-
gions. 3C methods can thus provide important mechan-
istic evidence linking GWAS variants to genes. Careful
selection of the appropriate cellular and environmental
context in which such variants act remains important,
given that chromatin interactions are dynamic and con-
text specific. Looping of chromatin can cause interaction
between two genetic loci or epistatic effects, and there is
evidence from gene expression studies that this is rela-
tively common in epistatic networks involving common
SNVs [87,88].
Advances in genome editing techniques
Model organisms have been very important in advan-
cing our understanding of regulatory variants and mod-
ulated genes (Box 1). Analysis of variants and putative
regulatory elements in an in vivo epigenomic regulatory
landscape (the native chromosomal context) for human
cell lines and primary cells is now more tractable fol-
lowing advances in genome editing technologies such as
transcription activator-like effector nucleases (TALENs)
[89] and in particular the RNA-guided ‘clustered regu-
larly interspaced short palindromic repeats’ (CRISPR)-
Cas nuclease system [90-92]. The latter approach uses
guide sequences (programmable sequence-specific CRISPR
RNA [93]) to direct cleavage by the non-specific Cas9 nu-
clease and generate double-strand breaks at target sites,
and either nonhomologous end joining or homology-
directed DNA repair using specific templates leads to the
desired insertions, deletions or substitutions at target sites
(Figure 3). The approach is highly specific, efficient, robust
and can be multiplexed to enable simultaneous genome
editing at multiple sites. Off-target effects can beminimized using a Cas9 nickase [92]. CRISPR-Cas9 has
been successfully used for positive and negative selection
screening in human cells using lentiviral delivery [94,95]
and to demonstrate functionality for particular regulatory
SNVs [52,61]. Lee and colleagues [61] discovered a
context-specific eQTL of SLFN5 and used CRISPR-Cas9
to demonstrate loss of inducibility by IFNβ on conversion
from the heterozygous to homozygous (common allele)
state in a human embryonic kidney cell line. Claussnitzer
and colleagues [52] used CRISPR-Cas9 and other tools to
characterize a type-2-diabetes-associated variant in the
PPARG2 gene; they replaced the endogenous risk allele in
a human pre-adipocyte cell strain with the non-risk allele
and showed increased expression of the transcript.
Integrative approaches and translational utility
Genomics-led research has significant potential to en-
hance drug discovery and enable more targeted use of
therapeutics by implicating particular genes and pathways
[8,96]. This requires greater focus on target discovery,
characterization and validation in academia combined
with better integration with industry. Combining GWAS
with eQTL analysis enables application of Mendelian
randomization approaches to infer causality for molecular
phenotypes [73,74]; this can enhance potential transla-
tional utility by indicating an intervention that could treat
the disease. Gene sets arising from GWAS are significantly
enriched for genes encoding known targets and associated
drugs in the worldwide drug pipeline; mismatches be-
tween current therapeutic indications and GWAS traits
are therefore opportunities for drug repurposing [97]. For
example, Sanseau and colleagues [97] identified registered
drugs or drugs in development that target TNFSF11, IL27
and ICOSLG as potential repurposing opportunities for
Crohn’s disease, given mismatches between GWAS associ-
ations with Crohn’s involving these genes and current
drug indications. To maximize the potential of GWAS for
therapeutics, and in particular for drug repurposing, it is
important to have better resolution of the identity of genes
modulated by GWAS variants so that associations can be
established between genes and traits. When an existing
drug is known to be effective in a given trait, it can then
be considered for use in a further trait that shows associ-
ation with the same target gene.
Two examples illustrate how knowledge of functional
regulatory variants and association with specific traits
can guide likely utility and application. Okada and col-
leagues [8] recently showed how an integrated bioinfor-
matics pipeline, using data from functional annotation,
cis-eQTL mapping, overlap with genes identified as
causing rare Mendelian traits (here, primary immuno-
deficiency disorders) and molecular pathway enrichment
analysis, could help prioritize and interpret results of






























Figure 3 Overview of the CRISPR-Cas9 system. Cas-9 is a nuclease that makes a double-strand break at a location defined by a guide RNA
[108]. The latter comprises a scaffold (red) and a 20-nucleotide guide sequence (blue) that pairs with the DNA target immediately upstream of
a 5’-NGG motif (this motif varies depending on the exact bacterial species of origin of the CRISPR used). There are two main approaches that
can be followed. (Left) Repair of the double-strand break by nonhomologous end joining can be used to knock out gene function though
incorporation of random indels at junction sites, where these occur within coding exons, leading to frameshift mutations and premature stop
codons. (Right) Homology-directed repair can enable precise genome editing through the use of dsDNA-targeting constructs flanking insertion
sequences or single-stranded DNA oligonucleotides to introduce single-nucleotide changes. Adapted with permission from [108].
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Figure 2 Overview of the Capture-C approach. Capture-C [36] enables mapping of chromatin interactions, in this example between a regulatory
element (within the region denoted by a red line) and a gene promoter (gray line). Crosslinking and high-efficiency restriction digestion followed
by proximity ligation (in which close proximity will favor ligation taking place, in this example generating red-gray lines in contrast to black lines
representing other ligation events) allows such interactions to be defined. A 3C library is generated, sonicated and end repair performed with ligation
of adaptors (dark gray boxes). Capture of target regions of interest (in this example target is region denoted by red line) involves oligonucleotide
capture technology (capture probes denoted by red hexagons with yellow centers). Sequencing using end-ligated adapters allows genome-wide
sites of interaction to be revealed. The approach can be multiplexed to several hundred targets.
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Box 2. Key questions
 What are the modulated genes underlying GWAS loci?
 By what specific mechanisms do particular disease-associated
regulatory variants act?
 How can we resolve regulatory variants in a disease context?
 Can epigenomic profiling of chromatin accessibility and
modifications be applied to small numbers of cells?
 Are genome editing techniques amenable to throughput
experiments?
 How can we use knowledge of disease association integrated
with functional evidence to repurpose existing therapeutics?
 Can knowledge of disease-associated regulatory variants and
modulated genes provide new drug targets for development?
 Will regulatory variants, in particular those acting in trans,
provide new insights into biological pathways and networks?
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GWAS variant in the tumor necrosis factor receptor
gene TNFR1 that can mimic effects of TNF-blocking
drugs. The functional variant was associated by GWAS
with multiple sclerosis, but not with other autoimmune
diseases, and mechanistically it was found to result in a
novel soluble form of TNFR1 that can block TNF. The
genetic data parallel clinical experience with anti-TNF
therapy, which in general is highly effective in auto-
immune disease but in multiple sclerosis can promote
onset or exacerbations. This work shows how knowing
the mechanism and spectrum of disease association
across different traits can help in developing and using
therapeutics.
Conclusions and future directions
The quest for regulatory genetic variants remains chal-
lenging but is facilitated by a number of recent develop-
ments, notably in terms of functional annotation and
tools for genome editing, mapping chromatin interac-
tions and identifying QTLs involving different inter-
mediate phenotypes such as gene expression at the
transcript and protein level. Integrative genomic ap-
proaches will further enable such work by allowing in-
vestigators to effectively combine and interrogate
complex and disparate genomic datasets [98,99]. A re-
curring theme across different approaches and datasets
is the functional context specificity of many regulatory
variants, requiring careful selection of experimental sys-
tems and of cell types and tissues. As our knowledge of
the complexities of gene regulation expands, the diverse
mechanisms of action of regulatory variants are being
recognized. Resolving such variants is of intrinsic bio-
logical interest, and fundamental to current efforts to
translate advances in genetic mapping of disease suscep-
tibility into clinical utility and therapeutic application.
Establishing mechanism and identifying specific modu-
lated genes and pathways is therefore a priority. Fortu-
nately, we increasingly have the tools for these purposes,
both to characterize variants and study them in a high-
throughput manner.
Key bottlenecks that need to be overcome include the
generation of functional genomics data in a broad range
of cell and tissue types relevant to disease (for other key
issues that remain to be resolved see Box 2). Cell num-
bers can be limiting for some technologies, and a range
of environmental contexts need to be considered. Mov-
ing to patient samples is challenging given heterogeneity
related, for example, to stage of disease and therapy, but
will be an essential component of further progress in
this area. QTL mapping has proven highly informative
but similarly requires large collections of samples, for
diverse cell types, in disease-relevant conditions. The
widespread adoption of new genome editing techniquesand ongoing refinement of these remarkable tools will
considerably advance our ability to generate mechanistic
insights into regulatory variants, but at present these lack
easy scalability for higher-throughput application. It is also
essential to consider the translational relevance of this
work, in particular how knowledge of regulatory variants
can inform drug discovery and repurposing, and how aca-
demia and pharma can work together to inform and
maximize the utility of genetic studies.
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